Attached files
| file | filename |
|---|---|
| EX-23.2 - EX-23.2 CONSENT OF EY - Apellis Pharmaceuticals, Inc. | apls-ex232_12.htm |
| EX-32.2 - EX-32.2 - Apellis Pharmaceuticals, Inc. | apls-ex322_9.htm |
| EX-32.1 - EX-32.1 - Apellis Pharmaceuticals, Inc. | apls-ex321_13.htm |
| EX-31.2 - EX-31.2 - Apellis Pharmaceuticals, Inc. | apls-ex312_6.htm |
| EX-31.1 - EX-31.1 - Apellis Pharmaceuticals, Inc. | apls-ex311_11.htm |
| EX-21.1 - EX-21.1 - Apellis Pharmaceuticals, Inc. | apls-ex211_7.htm |
| EX-10.26 - EX-10.26 - Apellis Pharmaceuticals, Inc. | apls-ex1026_87.htm |
| EX-10.25 - EX-10.25 - Apellis Pharmaceuticals, Inc. | apls-ex1025_88.htm |
| EX-10.17 - EX-10.17 - Apellis Pharmaceuticals, Inc. | apls-ex1017_217.htm |
| EX-4.4 - EX-4.4 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES E - Apellis Pharmaceuticals, Inc. | apls-ex44_10.htm |
| 10-K - 10-K - Apellis Pharmaceuticals, Inc. | apls-10k_20201231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in Registration Statement No. 333-235830 and 333-229091 on Form S-3 and Registration Statement No. 333-229876, 333-221528, 333-236708 and 333-236710 on Form S-8 of our reports dated February 25, 2021, relating to the financial statements of Apellis Pharmaceuticals, Inc. and its subsidiaries and the effectiveness of Apellis Pharmaceuticals, Inc. and its subsidiaries’ internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2020.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
February 25, 2021